Check-Cap (NASDAQ:CHEK) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Check-Cap (NASDAQ:CHEK) in a research note issued to investors on Tuesday. The firm issued a sell rating on the medical research company’s stock.

Check-Cap Trading Down 1.4 %

Shares of NASDAQ CHEK opened at $0.84 on Tuesday. Check-Cap has a 12-month low of $0.56 and a 12-month high of $3.45. The stock has a market cap of $4.92 million, a P/E ratio of -0.28 and a beta of 0.19. The business’s fifty day simple moving average is $0.91 and its 200-day simple moving average is $1.10.

About Check-Cap

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.